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Summary 
Objective:  
In the general population, obesity is associated with accelerated age-related 
cognitive decline. The impact of obesity in neurological populations who already have 
a heightened risk of cognitive decline is unknown. This study explored the 
relationship between obesity and cognitive underfunction in people with medically 
intractable epilepsy.   
 
Methods:  
Eighty one consecutive admissions for inpatient evaluation for medically intractable 
epilepsy (36 Females, 45 Males) underwent tests of memory and intellectual 
function. Optimal level of function was assessed using the National Adult Reading 
Test – Revised. Measures of underfunction were calculated by subtracting current 
measures of intellectual ability from the NART IQ. Body Mass Index (BMI) was used 
as an index of obesity. 
 
Results: 
 Twenty nine people had a BMI in the healthy range (36%), 31 were overweight 
(38%) and 21 were obese (26%). The heathy/overweight/obese groups did not differ 
in age at the time of assessment, age at seizure onset or optimal level of function 
(NART IQ). The obese group had a greater degree of suboptimal processing speed 
and demonstrated a greater degree of underfunction on the Full Scale IQ (FSIQ) 
measure compared to the healthy weight group. BMI accounted for 14% of the 
variance in underfunction in processing speed and 10% of the underfunction in FSIQ.  
Controlling for the effects of age, all measures of memory function were significantly 
correlated with BMI, with poorer scores associated with higher BMIs. 
 
Significance:  
A small, but significant proportion of the variance in memory function and intellectual 
underfunction in people with epilepsy is explained by BMI. Further work is needed to 
establish whether a reduction in BMI to within healthy limits is associated with 
improvements in cognitive function in this group.  
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Introduction 
In the general population, obesity is associated with accelerated age-related 
cognitive decline from middle age onwards[1] . Non dementing adults who are obese 
perform more poorly on standardised memory tests compared to individuals who are 
a healthy weight.[2, 3]  They also have smaller hippocampi [4], particularly those with 
central obesity[5]. Central obesity in middle age is also associated with an increased 
risk of developing dementia in old age [5]. The mechanisms underlying this 
relationship are complex and multifactorial. Obesity is a biomarker for the 
cardiovascular risk factors and diseases that have a direct impact on cognitive 
function, including diabetes and insulin resistance, elevated triglyceride levels, white 
matter disease, hypertension and hypercholesterolemia.[6]  
 
The impact of obesity on cognitive function in younger neurological populations who 
have pre-existing, heightened risks of cognitive dysfunction is unknown. The 
mechanisms of cognitive dysfunction in epilepsy are complex. The underlying 
pathology, antiepileptic medications and psychological factors all interact with the 
functional reserve of an individual to shape their cognitive profile. Cognitive functions 
change over time, with progressive deterioration associated with frequent 
generalised seizures and stepwise deteriorations following episodes of status 
epilepticus or seizure related injuries. [7, 8] 
 
A recent review found that the rates of obesity in people with epilepsy are similar to 
those found in the general population [9]. Whilst there are no associations between 
obesity and epilepsy type, duration, or aetiology, obesity rates are higher in patients 
with refractory than nonrefractory epilepsy (36.9% vs. 24.6%). Obesity is also more 
common in patients treated with polytherapy than those treated with monotherapy 
(37.7% vs. 25%). Some antiepileptic medications, particularly sodium valproate and 
pregabalin, have weight gain as a significant side effect [10]. 
 
This study explored the relationship between obesity and cognitive function and 
measures of decline on standardised indices of intellectual and memory function in 
people with medically intractable epilepsy. The prevalence of memory deficits in this 
population is already high6, due to a combination of the underlying pathology, 
treatment effects and psychiatric morbidities7 associated with the condition.  We 
hypothesised that effects of obesity on cognitive function seen in the general 
population would be evident in this neurological population. This study was designed 
to examine the variance in measures of intellectual decline and memory function that 






This was a cohort study of 81 consecutive adult patients who were referred for a 
neuropsychological assessment at our specialist epilepsy assessment service in 





All participants had a clinical diagnosis of epilepsy and were taking at least one 
antiepileptic medication at the time of assessment. At the time of the assessment, all 
participants were medically intractable i.e. they continued to experience seizures 
despite taking antiepileptic medications. All the participants in this study spoke 
English as a first language. Patients who had a diagnosis of Non Epileptic Attack 
Disorder (NEAD), or who were unable to complete the neuropsychological 
assessment due to sensory deficits or psychiatric disturbance were excluded from 
the study. The majority of the participants had focal epilepsy (n=77);  36 had a 
temporal lobe focus; 41 had an extra temporal focus or difficult to localise epilepsy; 
four had generalised epilepsy. All participants underwent a 3T structural MRI scan.  
See Table 1.  
 
The clinical and demographic characteristics of the sample are presented in Table 2. 
All participants underwent a medical interview at the time of their admission to the 
ward which documented their medical history and all previous diagnoses. None of 
the participants had been given a diagnosis of sleep apnoea at the time of their 
assessment, but sleep studies were not conducted during their admission to 
investigate this possibility. One participant had a diagnosis of type 1 diabetes; none 
had developed type 2 diabetes. 16 participants had evidence of white matter disease 
on MRI. In 5 of the 16, the white matter lesions were the only abnormalities evident 
on MRI. 
 
<<Table 2 about here>> 
 
Neuropsychological Tests:  
The IQs derived from the National Adult Reading Test – Revised[11] were used to 
provide a measure of each participants’ optimal level of intellectual function. (5.8 
points were subtracted to allow for the re-standardisation of the Wechsler Adult 
Intelligence Scale –IV - WAIS-IV). 
 
All participants completed WAIS-IV UK Edition [12]. The Verbal Comprehension, 
Perceptual Reasoning, Working Memory and Processing Speed indices were used 
as measures of intellectual function. The list learning and list retention score from the 
BIRT Memory and Information Processing Battery (BMIPB)[13] were used as 
measures of verbal learning and recall respectively. In the list learning task the 
patient is aurally presented with a list of 15 words to learn over trials and is then 
required to recall them following exposure to a distractor list. The design learning and 
design recall measures from the BMIPB were used as measures of visual learning 
and recall respectively. In the design learning task the patient is exposed for 10 
seconds to a design that has nine features and is required to reproduce it over five 
trials. Recall is tested following exposure to a distractor design. These tests have 
been described previously and have been shown to be sensitive to hippocampal 
pathology.[14, 15]. 
 
A measure of cognitive underfunction was calculated for each index of intellectual 
function by subtracting the index score from the NART IQ. In the general population 
BMI is negatively correlated with measures of intellectual function [16];  those with 
lower IQs are more likely to become obese than more able individuals [17]. In 
addition to underlying genetic factors, people with lower intellectual reserves, in 
particular deficits in executive functions, may make poorer diet choices than those 
with stronger intellectual abilities [17-19]. We controlled for this pattern in our study 
by creating individual measures of cognitive underfunction for each participant. By 
subtracting each patient’s current level of function from reliable measures of their 
optimal level of ability we ensured that the measures of intellectual underfunction we 
used in the analyses were relative to each patient’s optimal level of function rather 
than the norms in the general population. 
 
Reliable estimates of an individual’s optimal memory function are not available. 
Measures of underfunction can only be inferred using standardised 
neuropsychological tests. The memory scores were converted to z scores using the 
means and standard deviations from published age referenced norms for each test, 
to allow statistical comparisons [12,13]. 
 
76 of the participants completed the Hospital Anxiety and Depression Scale yielding 
scores for anxiety and depression. 
 
Body Mass Index:  
All patients undergo a general health screen when they are admitted to the hospital 
and their weight and height is recorded.  Body mass index was calculated using the 
following formula BMI = mass (kg)/(height (m))2. Participants with a BMI less than or 
equal to 18.4 were classified as underweight. Participants with a BMI between 18.5–
24.9 were classified as healthy weight. Participants with a BMI between 25 and 29.9 
were classified as overweight. Participants with a BMI of 30 or over were classified 
as obese. 
 
Statistical Methods:  
Partial correlations, controlling for age at time of assessment, were used to examine 
the relationship between BMI and neuropsychological test scores. ANOVAs were 
used to examine the differences between the healthy, overweight and obese groups 
on the neuropsychological measures. 
 
Regression analyses were used to examine the contribution of BMI to the variance in 
neuropsychological scores. The correlation coefficient squared (adjusted R2) was 
used as a measure of the amount of variability in each memory score that was 
explained by the model. 
 
Results 
Body Mass Index 
None of the participants were underweight; 29 had a BMI in the healthy range (36%), 
31 were overweight (38%) and 21 were obese (26%). There was no difference 
between the three groups (Healthy vs Overweight vs Obese) in their age at the time 
of assessment (F=1.3, df =2, p>0.05), age at seizure onset (f=0.3, df = 2, p>0.05) or 
optimal level of function NART IQ – (f=0.11, df=2, p>0.05). Similarly the three groups 
did not differ in their anxiety or depression scores on the HADS (Anxiety f=0.20, df=2, 
p>0.05; Depression f=0.44, df=2, p>0.05).  
The participants with white matter lesions did not significantly differ from those 
without, in their BMI (t=-1.7, df = 79, p>.05). 
 
Epilepsy Type and Antiepileptic Medications 
Epilepsy type was not associated with weight classification in this sample (Chi square 
= 5.6, df=5, p>0.05). See Table 1. Similarly, the number of antiepileptic medications 
taken was not related to the weight classifications (Chi square = 5.2, df=5, p>0.05). 
See Table 1. Seventeen participants were taking sodium valproate, an antiepileptic 
medication that has weight gain as recognised side effect. However in our sample 
the participants taking sodium valproate did not have a higher BMI than those who 
were not taking the drug (t=-0.63, df = 79, p>0.05). 
 
Intellectual Function 
The obese group demonstrated greater suboptimal function on the Processing Speed 
Index (f=5.8, df=2, p<0.01) and on the Full Scale IQ (f=3.6, df=2, p<0.05) compared 
to the healthy weight group.  
 
Unsurprisingly, BMI was significantly correlated with age, with higher BMIs seen in 
the older participants (Pearson corr =0.2, p<0.05). The relationship between the 
measures of suboptimal function (Current level – optimal level) and BMI were 
therefore explored using partial correlations to control for the effects of age on BMI. 
BMI was significantly correlated with the degree of underfunction in processing speed 
(corr = -.35, p<0.01), and Full Scale IQ (-.29, p<0.01). See Table 3. BMI accounted 
for 14% of the variance in decline in processing speed and 10% of the variance in 









All of the measures of memory function were significantly correlated with BMI. 
(Verbal Learning corr = -.32, p<0.01; Verbal Recall corr = -.27, p<0,01; Visual 
Learning corr =-.31, p<0.01; Visual Recall corr= -.19, p<0.05).   
 
Linear regression analyses were used to determine the contribution of BMI and the 
measures of anxiety and depression from the HADS to the variance in the memory 
scores. BMI was a significant predictor in the models generated for all four memory 
measures. The anxiety and depression scores were not significant variables. The 
adjusted R2 values were 0.13 for verbal learning, 0.09 for verbal recall, 0.08 for 
verbal recall, 0.09 for visual recall. See Table 4. 
Discussion 
BMI is correlated with the extent of underfunction on a global measure of IQ and 
slowed processing speed in people with medically intractable epilepsy. The more 
overweight the patient, the higher the discrepancy between measures of their optimal 
level of function and their current level of function. BMI accounts for up to 14% of the 
variance in slowed processing speed. Approximately ten percent of the variance in 
memory scores on standardised tests of verbal and visual learning can be also be 
explained by BMI. Our regression analyses suggest that BMI is a more powerful 
predictor of memory impairment than measures of anxiety and depression. Although 
the participants in this study all had medically intractable epilepsy, they were a 
heterogeneous sample in terms of their underlying pathology, type of epilepsy and 
anti epileptic medication regimes. Nevertheless a high BMI emerged as a significant 
predictor of cognitive underfunction. 
 
With an average age in their mid-thirties, the participants in this study are significantly 
younger than those who are typically reported in the obesity/cognitive decline 
literature. This explains in part, the absence of obesity related health problems such 
as diabetes and sleep apnoea in this sample. However, it is noteworthy that the 
presence of white matter lesions was not related to BMI at this stage in the 
participant’s life. The mechanisms driving the relationship between obesity and 
cognitive function in this sample are unknown and deserve further study.  
 
Limitations:  
Our measure of intellectual underfunction was based on the NART which has a 
restricted range in its estimates of premorbid IQ [20]. We did not have data on the 
educational or socioeconomic status of the participants, although these measures 
can also be of limited value in people whose education and employment 
opportunities have been limited by their condition. This was a brief pilot study, based 
on an audit of clinical data, designed to explore the value of this avenue of research 
in this patient group. Ideally cognitive decline should be measured in a longitudinal 
study design.  
 
BMI is a relatively crude measure of health and does not take into account muscle 
mass, fat distribution or other measures of cardiovascular health and fitness. The 
presence of central obesity may be a particular risk factor for memory decline and 
accelerated hippocampal volume loss in the general population [5]. Further work is 
underway to examine the relationship between measures of cognitive decline in this 
population and more detailed measures of cardio vascular fitness including hip/waist 
ratio, blood pressure, eGFR and ECG data. 
 
We did not examine dosage of individual medications as this is difficult to compare 
across different medications. However the prescription patterns and dosages for the 
majority of antiepileptic medications are not routinely adjusted for the weight of the 
patient and this is unlikely to account for our findings. 
 
Interpretation:  
Whilst correlation does not equate to causation, these findings suggest the possibility 
of cognitive improvement following a reduction in BMI in this group. In the healthy 
population improvements on tests of memory and executive function have been 
recorded following weight loss in obese individuals [4, 21, 22].  Although further work 
is necessary to see whether this pattern holds true in this population, this raises the 
possibility that lifestyle counselling could form an integral part of neuropsychological 
rehabilitation packages for cognitive complaints in this group. 
Table 1.   MRI Pathology 
 Frequency Percent 
 
Normal: No abnormality detected 35 43.2 
Hippocampal Sclerosis 12 14.8 
Cortical Dysplasia 11 13.6 
Dysembryoplastic Neuroepithelial Tumour 2 2.5 
Structural Lesion 8 9.9 
Hyper intense lesion 2 2.5 
White Matter Disease 5 6.2 
Surgery 2 2.5 
Infarct 4 4.9 
Total 81 100.0 
 
 
Table 2: Clinical & Demographic Characteristics of the Participants 
 






Epilepsy Type Focal n=28 
(n= 17 temporal) 
Generalised n=1 
 Focal n=30 
(n= 6 temporal) 
Generalised n=1 
 Focal n=19 
(n= 5 temporal) 
Generalised n=2 
No. of AEDs 1 - n=7 
2 - n=13 
>2 - n=9 
1  - n=3 
2 - n=12 
>2 - n=16 
1 - n=2 
2 - n=7 
>2 - n=12 
Age at Assessment 32.0 (10.5) 35.6 (11.0) 36.5 (10.0) 
Age at epilepsy onset 18.2 (6.9) 18.2 (12.5) 15.8 (12.3) 
 
Table 3: Relationship between BMI and Measures of Intellectual Function 
 
 Partial Correlation 
with BMI (controlling 
for age) 





Corr = -.11 n.s 0.01 1% 
Perceptual Reasoning 
Underfunction  Index 
Corr = -.10 n.s 0.01 1% 
Working Memory 
Underfunction  Index 
Corr =-.17 n.s 0.02 2% 
Processing Speed 
Underfunction Index 
Corr =-.36 (p<0.001) 0.14 14% 
Full Scale IQ  
Underfunction Index  
Corr = -.31 (p<0.01) 0.09 10% 
 
n.s. not significant p>0.05 
 
 
Table 4. Linear Regression Analyses: Memory scores as independent  
               variables &  BMI, anxiety & depression as predictor variables. 
Verbal Learning Model B Std. Error t Sig. 
(Constant) 67.476 6.273 10.757 .000 
BMI -.657 .216 -3.037 .003 
HADS Anxiety -.139 .355 -.392 .696 
HADS Depression -.413 .367 -1.124 .265 
Visual Learning Model     
(Constant) 50.230 4.473 11.229 .000 
BMI -.500 .154 -3.241 .002 
HADS Anxiety -.356 .253 -1.408 .164 
HADS Depression .182 .261 .697 .488 
Verbal Recall Model     
(Constant) 15.258 1.975 7.724 .000 
BMI -.165 .068 -2.420 .018 
HADSanx -.075 .112 -.666 .508 
HADSdep -.106 .116 -.921 .360 
Visual Recall Model     
(Constant) 10.773 1.211 8.893 .000 
BMI -.100 .042 -2.391 .019 
HADS Anxiety -.086 .068 -1.249 .216 
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